SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation
Pilar Gallego(Hospital Universitario Virgen de la Arrixaca), Gregory Y.H. Lip(Medical University of Białystok), Vicente Vicente(Centro Regional de Hemodonación), Vanessa Roldán(Hospital Universitario Virgen de la Arrixaca), Mariano Valdés(Universidad de Murcia), José Miguel Cantón Gálvez(Universidad de Murcia), Francisco Marı́n(Instituto Murciano de Investigación Biosanitaria)
Cited by 125
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Antithrombotic Therapy for Atrial Fibrillation
|CHEST Journal|2012|919